Growth factor rich plasma (GRP) is a novel technology that has meant significant clinical progress in the medical field and is starting to be used as an alternative for treating cases of premature ovarian insufficiency and diminished ovarian reserve. The technology is based on the principles of regenerative medicine, the purpose of which is to restore “the biological environment,” imitating and accelerating the body’s own regeneration processes.